Cardiovascular gene therapy - Aventis Gencell/Oxford BioMedica
Latest Information Update: 13 Aug 2003
At a glance
- Originator Oxford BioMedica
- Developer Aventis Gencell
- Class Gene therapies
- Mechanism of Action Angiogenesis inducing agents; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ischaemic heart disorders; Peripheral arterial disorders
Most Recent Events
- 13 Aug 2003 Discontinued - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 13 Aug 2003 Discontinued - Preclinical for Peripheral arterial disorders in USA (unspecified route)
- 24 Dec 1999 Rhône-Poulenc Rorer Gencell is now Aventis Gencell